natgillin/translations-raw huggingface dataset:
The resulting mixture was extracted with ethyl acetate (3×). 
Rezultirajuća smjesa se ekstrahira s etil acetatom (3x).
a modulator of a mutant CFTR protein used for the manufacture of a medication for the treatment of disease associated with CFTR protein malfunction, wherein the modulator comprises a compound of formula (I) its tautomers, E and Z geometrical isomers, optically active forms or its pharmaceutically acceptable salts thereof or complexes thereof; 
Tvar opće formule (I): [image] njeni tautomeri, E i Z geometrijski izomeri, optički aktivni oblici kao što su enantiomeri, dijastereoizomeri i njihovi racematni oblici ili smjese stereoizomernih oblika ili njihovih farmaceutski prihvatljivih soli ili kompleksa; pri čemu je Z1 nezavisno odabran iz grupe koja se sastoji od:
A compound of paragraph 13, of formula (I-L): 
Spoj sukladno patentnom zahtjevu 5, formule (I-L): ž a
After cooling at 20 °C the solution was stirred for 1 hour and cooled to -10 °C (± 2 °C). 
Nakon hlađenja na 20 "C otopina je miješana tijekom 1 sata i ohlađena na -10 *C (+ 2 *C).
iii) characterized by one or more peaks expressed in 2-theta ± 0.2 at about 8.9, 14.8, 16.5, 18.6, 20.9, 22.2, and 23.4 degrees in an X-Ray powder diffraction pattern obtained using Cu K alpha radiation; and/or iv) characterized as having an X-ray powder diffraction pattern substantially the same as that shown in Figure 1g; 
ii) koji se odlikuje s jednim ili više vrhova izraženim u 2-theta ± 0,2 na oko 8,9; 14,8; 16,5; 18,6; 20,9; 22,2 i 23,4 stupnjeva u rendgenskom difrakcijskom prahu dobivenom primjenom Cu K alfa zračenja; i/ili iii) koji se odlikuje time da ima rendgenski difrakcijski prah u osnovi isti kao onaj prikazan na Slici 1g;
A solid cosmetic composition according to claim 1, wherein the soft vegetable butter is selected from aloe butter, avocado butter, cupuacu butter, macadamia nut butter, mango butter, olive butter, shea butter, coconut butter, pumpkin seed butter, peanut butter, almond butter, coffee bean butter, refined butter, hemp seed butter, mochacchino butter, pistachio nut butter, shealoe butter, and mixtures thereof. 
Kruti kozmetički pripravak prema bilo kojem od zahtjeva 1 do 4, naznačen time što je mekani biljni maslac odabran od aloe maslaca, avokado maslaca, kupuaku maslaca, maslaca od makadamija oraščića, mango maslaca, maslaca od masline, shea maslaca, kokosovog maslaca, maslaca od sjemenki bundeve, kikiriki maslaca, te bademovog maslaca, maslaca od zrna kave, rafiniranog maslaca, maslaca od konoplje, Mochacchino maslaca, pistacio maslaca, Shealoe maslaca i njihovih smjesa.
The compound of claim 3 where Y is cyclopentyl, cyclohexyl, thienyl, furyl, pyridinyl, or optionally substituted phenyl. 
Spoj iz zahtjeva 3, naznačen time, da Y je ciklopentil, cikloheksil, tienil, furil, piridinil, ili po izboru supstituirani fenil.
All prior teachings acknowledged above are hereby incorporated by reference. No acknowledgement of any prior published document herein should be taken to be an admission or representation that the teaching thereof was common general knowledge in Australia or elsewhere at the date hereof. A delayed release drug formulation for oral administration to deliver a drug to the colon of a subject, said formulation comprising a core and a coating for the core, the core comprising a drug and the coating comprising an outer layer and an inner layer, wherein the outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria and a second polymeric material which has a pH threshold at about pH 5 or above, and wherein the inner layer comprises a third polymeric material which is a non-ionic polymer that is soluble in intestinal fluid, and at least one additive selected from a buffer agent and a base. 
Postupak proizvodnje formulacije lijeka s odloženim otpuštanjem za oralnu primjenu radi davanja lijeka u debelo crijevo sukladno patentnom zahtjevu 1, naznačeno time, da navedeni postupak obuhvaća: formiranje jezgre koje sadrži lijek; premazivanje te jezgre pomoću pripravka za oblaganje koji sadrži treći polimerni materijal koji je topljiv u crijevnoj tekućini, ili gastrointestinalnoj tekućini, u sustavu otapala da se formira unutrašnja obložena jezgra; i premazivanje unutarnje obložene jezgre s vanjskim premaznim pripravkom koji sadrži prvi polimerni materijal koji je osjetljiv na napad bakterija debelog crijeva i drugi polimerni materijal koji ima prag pH od pH 6 ili iznad u sustavu otapala, da se dobije vanjska obložena jezgra; naznačeno time, da je taj treći polimerni materijal je neionski polimer, i navedeni unutarnji pripravak za oblaganje sadrži najmanje jedan aditiv odabran iz puferskog sredstva i baze.
Use according to any one of the preceding claims, characterized in that said at least one polyethylenimine is added to said suspension in an amount of from 1000 to 5000 mg, and more preferably of 1300 to 4000 mg, per liter of the aqueous phase of said suspension. 
Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time da navedeni barem jedan polietilenimin je dodan u navedenu suspenziju u količini od 1000 do 5000 mg, te još poželjnije od 1300 do 4000 mg po litri vodene faze navedene suspenzije.
A nasal spray device as claimed in any preceding claim, wherein the propellant constitutes 80% to 99% w/w, preferably 90 to 98% w/w, based on the total weight of the formulation. 
Uređaj za sprej za nos sukladno Zahtjevu 1, pri čemu je suotapalo prisutno u količini od 0.5 do 20% w/w, temeljem ukupne težine farmaceutske formulacije.
A compound of formula I for use as defined in claim 1wherein the compound of formula I and said one or more agents are administered sequentially. 
Spoj formule I za uporabu kao što je definirano u patentnom zahtjevu 1 naznačen time što se spoj formule Ii navedeno jedno ili više sredstava primjenjuju uzastopno.
The dry concentrate of claim 1 IS CHARACTERIZED BY THAT it consists of raw materials measured in the following mass proportions: lyophilized beebread 0,0175 mass%, chelate iron (20%) 0,425 mass%, vitamin C 0,4 mass%, anhydrous citric acid 3,75 mass%, micronized SiO2 1,0 mass%, mixture of natural aroma and color 4 mass%, and sucrose 90,4075 mass%. 
Suhi koncentrat prema zahtjevu 1, naznačen time, što ga čine sirovine izmjerene u slijedećim masenim odnosima: liofilizirana matična mliječ 0,0175 mas %, kelatno željezo (20%) 0,425 mas %, vitamin C 0,4 mas %, anhidrirana limunska kiselina 3,75 mas %, mikronizirani SiO> 1,0 mas %, mješavina prirodne arome i boje 4 mas %, i saharoza 90,4075 mas %.
is a solution containing at least about 50% gelatin; or 
tekući proteinski materijal je otopina koja sadrži najmanje oko 35 % želatine;
is C6-C10-aryl, such as phenyl, and "*" means a chiral center with absolute stereochemistry (R) or (S), with an acidic reagent to provide the compound of formula (I). 
R6 je Cs-Cro-aril, kao što je fenil, i "*" znači kiralni centar s apsolutnom stereokemijom (R) ili (S), s kiselinskim reagensom, za dobivanje spoja formule (I).
Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence can be preferred in some circumstances. 
Nadalje, supstitucija sa težim izotopima poput deuterija (t.j. *H) može pribaviti određene terapeutske prednosti koje proizlaze iz veće metaboličke stabilnosti (t.j. povećanog poluživota trajanja in vivo ili smanjenih zahtjeva za dozom) te stoga može biti povoljna u određenim prilikama.
At the mouth end 15 of this element there is a low efficiency cellulose acetate filter plug 45. 
Na djelu 15 usnog kraja ovog elementa postoji filter čep 45 niske efikasnosti od acetata celuloze.
A represents an alkylene group having from 1 to 4 carbon atoms; 
A predstavlja alkilensku skupinu s 1 do 4 atoma ugljika;
In this process crushed, washed and dried waste-polyester flakes are heated to a temperature of 130° C.±5° C. At this temperature is added a defined modifying agent in an amount from 4% by weight to 6% by weight, referred to the total mass. 
U ovom se procesu zagrijavaju zdrobljene, isprane i osušene pahuljice otpadnog poliestera do temperature od 130%C + 5?C. Pri toj se temperaturi dodaje definirani modificirajući agens u količini od 4% težine do 6% težine, u odnosu na ukupnu masu.
The invention further concerns any of the above-described isolated antibodies or immunoreactive fragments thereof, wherein the antibody is a modified antibody that comprises a variant human IgG1 Fc region, wherein the variant human IgG1 Fc region comprises at least one amino acid modification relative to the Fc region of the parent of the antibody, the amino acid modification(s) comprising amino acid modification(s) that alters the affinity or avidity of the variant Fc region for binding to an FcYR such that the modified antibody exhibits enhanced effector function relative to the parent antibody. 
Molekula koja se veže na B7-H3 u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačena time što navedena molekula koja se veže na B7-H3 sadrži varijantu područja Fc ljudskog IgG1, gdje navedena varijanta područja Fc ljudskog IgG1 sadrži najmanje jednu aminokiselinsku modifikaciju u odnosu na divlji tip područja Fc, gdje jedna ili više navedenih aminokiselinskih modifikacija sadrži jednu ili više aminokiselinskih modifikacija koje tako mijenjaju afinitet ili aviditet navedene varijante područja Fc kod vezanja na FcyR da navedena molekula pokazuje pojačanu efektorsku funkciju u odnosu na navedeni divlji tip područja Fc.
The method according to Claim 8 wherein the second solvent in step c2 is selected from the group consisting of toluene, alkylsubstituted aromatics and long chain alkanes. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time, da je drugo otapalo u koraku c2 odabrano iz skupine koja se sastoji od toluena, alkilsupstituiranog aromatika i dugolančanih alkana.
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to at least five CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, CCL15/HCC-2, and CCL23/MPIF-1, and which does not bind to CCL2/MCP-1, comprising heavy and light chain CDR sequence combinations (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) selected from the group consisting of SEQ ID NO: 3/4/5/8/9/10 and 53/54/55/58/59/60, or which competes for binding to at least five CC chemokines selected from CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, CCL15/HCC-2, and CCL23/MPIF-1, with an antibody or antigen binding fragment comprising heavy and light chain CDR sequence combinations selected from the group consisting of SEQ ID NO: 3/4/5/8/9/10 and 53/54/55/58/59/60. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje pet CC kemokina odabranih iz skupine koja se sastoji od CCL3/MIP-1a, CCLA/MIP-1$f, CCLS/RANTES, CCL15/HCC-2, i CCL23/MPIF-1, i koji se ne veže na CCL2/MCP-1, koji sadrži kombinacije CDR nizova teških i lakih lanaca (HCDR1/HCDR2/HCDR3/LCDRI1I/LCDR2/LCDR3) odabranih iz skupine koja se sastoji od SEQ ID NO: 3/4/5/8/9/10 i 53/54/55/58/59/60, ili koji se natječe za vezanje na najmanje pet CC kemokina odabranih iz CCL3/MIP-la, CCL4/MIP-18, CCLS/RANTES, CCL15/HCC-2, i CCL23/MPIF-1, s antitijelima, ili fragmentom koji veže antigen koji sadrži kombinacije CDR slijeda teškog i lakog lanca odabranih iz skupine koja se sastoji od SEQ ID NO: 3/4/5/8/9/10 1 53/54/55/58/59/60.
said film coating composition comprises ethylcellulose and guar gum, 
(ii) navedeni sastav za oblaganje filmom obuhvaća etilcelulozu 1 guar gumu;
The pharmaceutical composition according to claim 19 or claim 20, wherein the compound is a compound of claim 17. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 19 ili patentnim zahtjevom 20, naznačen time što je spoj spoj u skladu s patentnim zahtjevom 17.
is hydrogen, Har is 1-methyl-1H-pyridin-2-one-5-yl, or an enantiomer, a salt, an N-oxide or a salt of an enantiomer or N-oxide of this compound. 
je vodik, Har je 1-metil-1H-piridin-2-on-5-il, ili njegov enantiomer, njegova sol, njegov N-oksid ili sol od enantiomera ili N-oksid od toga spoja.
In said modification, it is intended to proceed according to the 2nd embodiment, whereby, however, in place of each 6th layer of an oak board, it is conceivable to incorporate a layer of a thin aluminum plate (thickness 0.8 mm) into the layer composite and to fix said composite by gluing. 
Modifikacija Namjera je da se u navedenoj modifikaciji postupi u skladu s drugim ostvarenjem, pri čemu, međutim, umjesto svakog šestog sloja ploče od hrasta, moguće je ugraditi sloj tanke aluminijske ploče (debljine 0.8 mm) u složeni sloj i učvrstiti navedeni složeni sloj lijepljenjem.
reacting the aqueous suspension of succinylcasein obtained in step (a) with at least one iron salt to form ferro-succinylcasein. 
reakcije vodene suspenzije sukcinilkazeina, dobivene u koraku (a), s najmanje jednom željeznom solju, kako bi se dobilo fero-sukcinilkazein.
Modulator of formula (I) according to claim 1, for use in the treatment of cystic fibrosis wherein it has effect on mutant CFTR protein, wherein said CFTR mutation is a mutation AF508-CFTR, or another mutation of class II. 
Modulator formule (I) u skladu s patentnim zahtjevom 1, za uporabu u liječenju cistične fibroze pri čemu on ima učinak na mutirani CFTR protein, pri čemu je navedena mutacija CFTR mutacija ∆F508-CFTR, ili druga mutacije klase II.
All methods include the step of bringing the active ingredient(s) into association with the carrier. 
Svi navedeni postupci uključuju korak u kojem se djelatni sastojak (sastojci) povezuju s nosačem.
3 shows the chromatogram of the fractionation of the r-hIL-18BP elution peak in a MEP HYPERCEL® column. 
Slika 3 prikazuje kromatogram frakcionacije eluacijskog peak-a r-hIL-18BP na koloni MEP HyperCel
pouring the melt on to the periphery of the first rotor; 
(33) Država ili organizacija podnošenja prve prijave: EP
The object of the present invention is a composition comprising shellac and/or a salt thereof and sodium starch glycolate and at least one physiologically acceptable excipient. 
PATENTNI ZAHTJEVI Pripravak koji sadrži šelak i/ili njegovu sol, natrijev škrobni glikolat i najmanje jednu fiziološki prihvatljivu pomoćnu tvar, naznačen time što je pripravak za oblaganje.
Examples of suitable disaccharides for the compositions of this invention include lactose, trehalose, sucrose, and combinations thereof. 
Primjeri pogodnih disaharida za smjese ovog izuma obuhvaćaju laktozu, trehalozu, saharozu i njihove kombinacije.
Workup of the reaction preferably comprises washing the reaction mixture with an aqueous solution and concentrating the washed reaction mixture by removal of solvents to afford a residue comprising the boronic ester compound of formula (I). 
(c) ispiranje reakcijske smjese vodenom otopinom; i (d) koncentriranje isprane reakcijske smjese uklanjanjem otapala da bi se dobio ostatak koji sadrži spoj ester organobornce kiseline formulc (7).
an NDV-F gene having the polynucleotide sequence set forth in SEQ ID NO: 5, operably linked to an SV40 promoter and an SV40 polyA signal and inserted into the IG1 locus of the HVT genome. 
NDV-F-gen koji ima polinukleotidnu sekvencu prikazanu u SEQ ID BR:5, koji je operativno povezan s SV40 promotorom i SV40 poliA-signalom, i umetnut je u IG1 lokus od HVT genoma.
Preferably said mouthpiece (5) projects from said body (7); 
Poželjno, navedeni kljun (5) strši iz navedenog tijela (7).
A method for treating diabetic neuropathy, diabetic gangrene, peripheral circulatory disturbance, chronic arterial occlusion, intermittent claudication, scleroderma, thrombosis, pulmonary hypertension, myocardial infarction, angina, glomerulonephritis, diabetic nephropathy, chronic renal failure, bronchial asthma, interstitial pneumonia (pulmonary fibrosis), chronic obstructive pulmonary disease, inflammatory bowel disease, or symptoms associated with spinal canal stenosis, comprising the step of administering the crystal of claim 1 as an active ingredient to a subject. 
Spoj, naznačen time što je namijenjen upotrebi u liječenju dijabetične neuropatije, dijabetične gangrene, poremećaja perifernog krvotoka, kroničnog začepljenja arterija, povremenog šepanja, tromboze, plućne hipertenzije, infarkta miokarda, angine, glomerulonefritisa, dijabetične nefropatije, kronične insuficijencije bubrega, bronhijalne astme, intersticijske pneumonije (plućne fibroze), skleroderme, kronične opstruktivne plućne bolesti, upalne bolesti crijeva, tubulointersticijskog nefritisa, ili simptoma povezanih s lumbalnom stenozom kralježničnog kanala, gdje je spoj kristal u skladu s patentnim zahtjevom 1.
● 5-Lipoxygenase (5-LO) inhibitors or 5-lipoxygenase activating protein (FLAP) antagonists; 
-Lipoksigenaza (5-LO) inhibitori ili antagonisti 5-lipoksigenaza aktivirajućeg proteina (FLAP);
A gum separated from the. reaction mixture, which was isolated by decantation of the aqueous layer and then dissolved in ethyl acetate (2 1.). 
Odvaja se guma iz reakcijske smjese, koja se izolira dekantacijom vodenog sloja i tada se otopi u etilacetatu (2 1.).
The planar element according to claim 11, wherein the planar element is one of a cavity or cavity wall. 
Ravni element prema barem jednom od zahtjeva 1 do 6, naznačen time da je konstruiran kao šupljina ili šuplja stjenka.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of general formula (I) and/or a salt or stereoisomer thereof as defined in claims 1-6. 
Farmaceutski pripravak, naznačen time da sadrži farmaceutski prihvatljiv nosač i farmaceutski učinkovitu količinu spoja opće formule (21) ifili njegove soli ili stereoizomera kao što je definirano u patentnim zahtjevima 1-6.
Ready-meal package (1) according to one of the preceding claims, wherein said food product (20) is made up of pasta or rice and said secondary food product (30) is made up of a sauce or cream. 
Pakct gotove hranc (1) prema jednom od prethodnih zahtjeva, gdje je glavni prehrambeni proizvod (20) tjestenina ili riža, a sekundarni prehrambeni proizvod (30) je umak ili krema.
An anti-tumor agent according to Claim 24, wherein tumor is a pancreatic cancer, a gastric cancer, a colorectal cancer, a breast cancer, a prostate cancer, a lung cancer, a renal cancer, a brain tumor or an ovarian cancer. 
HR P20130719 TI Anti-tumorsko sredstvo prema zahtjevu 24, naznačen time da tumor je karcinom gušterače, karcinom želuca, karcinom debelog crijeva, karcinom dojke, karcinom prostate, karcinom pluća, karcinom bubrega, tumor mozga ili karcinom jajnika.
The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention. A method for transporting therapeutic cells to a damaged or degenerating or injured central nervous system of a mammal, the damage or degeneration caused by a neurological disease or condition that results in the loss or death of central nervous system cells, comprising: 
Terapijske stanice, koje nisu ljudske embrionske matične stanice, namijenjene upotrebi u liječenju oštećenog ili degeneriranog ili ozlijeđenog središnjog živčanog sustava životinje, gdje je oštećenje ili degeneracija rezultat neurološke bolesti ili stanja koje uzrokuje gubitak ili smrt stanica središnjeg živčanog sustava, naznačene time što se navedeno liječenje sastoji u: primjeni terapijskih stanica u gornju trećinu nosne šupljine životinje; i omogućavanju da terapijske stanice dospiju u oštećeni središnji živčani sustav zaobilaženjem krvno-moždane barijere.
The compounds and compositions of the present invention are also useful for lowering serum triglyceride levels. 
Spojevi i pripravci prema ovom izumu također su korisni za snižavanje razina triglicerida u serumu.
subjecting together part B and the product of step d) to a reactor for biomass hydrolysis to obtain soluble sugars. 
izlaganja zajedno dijela Đ i produkta iz koraka d) reaktoru za hidrolizu biomase kako bi se dobili topljivi šećeri.
The fabric according to claim 1, characterized in that said first inner layer (11) is formed by strips of hydrophobic fabric (16, 416), each of which is arranged so as to affect a corresponding rib of said ribs (15, 115, 415). 
Tkanina u skladu s patentnim zahtjevom 1, naznačena time, da se prvi unutarnji sloj (11) sastoji od traka hidrofobne tkanine (16, 416), od kojih je svaka postavljena tako da djeluje na odgovarajuće rebro navedenih rebara
Q is -NH- or -CH2-; symbols m and n, independently, are whole numbers from 0 to 4; 
Q je ili -CH>-; simboli m i n, neovisno, su cijeli brojevi, od 0 do 4;
A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier, excipient and/or stabilizer. 
Farmaceutski sastav, naznačen time, da sadrži protutijelo prema bilo kojem od zahtjeva 1 do 9 i farmaceutski prihvatljiv nosač.
astrocytoma, neuroblastoma, glioma and schwannomas; melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma. 
HR P20110245 TI astrocitom, neuroblastom, gliom i neurilemomi; melanom, seminom, teratokarcinom, osteosarkom, pigmentna kseroderma, keratoksantom, rak folikula štitnjače i Kaposijev sarkom.
Nepafenac free or substantially free of chlorination by-products. 
Nepafenak bez ili u biti bez nusproizvoda kloriranja.
A glucocorticoid contained in a delayed-release dosage form for use in the treatment of a patient suffering from morning stiffness and pain due to an underlying rheumatic disease and/or osteoarthritis, wherein said treatment is administered once daily in the evening for at least two weeks. 
Glukokortikoid sadržan u obliku doziranja s odgođenim otpuštanjem za uporabu u liječenju bolesnika koji pate od jutarnje ukočenosti i boli zbog reumatske podloge bolesti i/ili osteoartritisa, pri čemu se navedeno liječenje provodi davanjem lijeka jednom dnevno kroz najmanje dva tjedna.
determination of a mean offset of the symbols of the sequence. 
- < određivanje srednjeg odlaznog pomaka simbola sekvence.
The solution according to claim 1, wherein carnitine is comprised in the range of 0.02% w/v to 0.45% w/v. 
Otopina u skladu s patentnim zahtjevom 1, naznačena time što karnitin dolazi u rasponu od 0,02% tež./vol. do 0,45% tež./vol.
A terminal apparatus that transmits control information on a plurality of layers, the apparatus comprising: 
Terminalni uređaj (200) koji prenosi kontrolnu informaciju u pluralitetu slojeva, uređaj sadržeći:
A compound according to claim 1 wherein W2 is a phenyl ring and L is a bond represented by the general formula (IC): wherein R6 is selected from methyl, ethyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, methoxymethyl, trifluoromethyl and difluoromethyl and R1, R2, R3, R4, R5, R7, A, L1, W1, L2, m, n, k and x' are as defined in claim 1 for compounds of formula (I), pharmaceutically acceptable salt and solvate thereof. 
(Rin, A (IC) pri čemu je Ry odabran od metila, etila, hidroksimetila, 1-hidroksietila, 2-hidroksietila, metoksimetila, trifluormetila 1 difluormetila te su R,, R2, Rs, Ra, Rs, Ry, A, Li, Wii, Lo, m, nj, ki x kao što su definirani u patentnom zahtjevu 1 za spojeve formule (1), njihovu farmaceutski prihvatljivu sol 1 solvat.
A non-limiting example of a method of synthesis of compounds of the invention: In an initial step, the first region (A) is synthesized (ii), followed by region B. In some embodiments the third region is then attached to region B (iii), optionally via a phosphate nucleoside linkage (or e.g. a trialzol linkage). 
Oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, da je druga regija kovalentno vezana na treću regiju na terminalnom nukleozidu druge regije (tj. 3\ ili 5/ završetak, ovisno o položaju prve regije).